Industrial Filtration Market Size, Share | Industry Report 2033
The global industrial filtration market is projected to reach USD 53.81 billion by 2033, growing at a CAGR of 4.6% from 2025 to 2033, driven by increasing industrial activity, stricter environmental regulations, and demand for cleaner air and water. North America currently dominates the market, with the U.S. leading the region, while Asia Pacific is expected to be the fastest-growing market. Key trends include the integration of smart technologies, a focus on sustainability, and customized filtration solutions, with liquid filtration holding the largest market share and air filtration anticipated to experience the fastest growth.
$3.8 Billion Negative Pressure Wound Therapy (NPWT) Devices
The global market for Negative Pressure Wound Therapy (NPWT) devices is projected to grow from $2.9 billion in 2025 to $3.8 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.9%. This growth is driven by the increasing demand for advanced wound healing technologies, particularly for managing diabetic foot ulcers and surgical site infections. The report analyzes market trends, applications, end-users, and regional dynamics, profiling major companies such as Solventum and Smith+Nephew.
$3.8 Billion Negative Pressure Wound Therapy (NPWT) Devices Market Assessment, 22 - Featuring Solventum, Smith+Nephew, Cardinal Health, Molnlycke Health Care, ConvaTec Group and Other Key Players
The global Negative Pressure Wound Therapy (NPWT) devices market is projected to grow from $2.9 billion in 2025 to $3.8 billion by 2030, at a CAGR of 5.9%. This growth is driven by the increasing demand for advanced wound healing technologies, particularly for diabetic foot ulcers and surgical site infections. The report provides a comprehensive analysis of market trends, regional dynamics, key players, and future growth prospects in the NPWT sector.
(SOLV) Movement as an Input in Quant Signal Sets
This article analyzes Solventum Corporation (NASDAQ: SOLV) using AI models to generate trading strategies. It highlights weak near-term sentiment but identifies a mid-channel oscillation pattern, presenting a 24.7:1 risk-reward short setup. The piece details position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis, including support and resistance levels.
The Bull Case For Align Technology (ALGN) Could Change Following New Guidance, Buybacks, And Research Push
Align Technology (ALGN) announced fourth-quarter 2025 results, including sales of US$1,047.56 million and net income of US$135.76 million, alongside a 2026 revenue guidance of 3% to 4% growth worldwide. The company also completed a US$171.57 million share repurchase program and expanded its collaboration with the University of Bern for oral health research. These developments, particularly the solid revenue guidance and growing international case volumes, are expected to influence the investment narrative for Align Technology.
US infrastructure firm Solv Energy prices IPO at USD 5bn valuation
US infrastructure firm Solv Energy is reportedly pricing its IPO at a valuation of USD 5 billion. The article notes that the filing date for the article was February 11, 2026. Solv Energy operates in the solar power and energy storage sectors within the USA and Canada.
Mizuho Upgrades Solventum (SOLV), Cites Optimistic Dental Outlook, Acera Acquisition
Mizuho upgraded Solventum (SOLV) from Neutral to Outperform, raising its price target to $100 due to an optimistic dental industry outlook and the acquisition of Acera. Stifel also raised its price target to $105, expecting a favorable MedTech outlook in 2026. Solventum's acquisition of Acera Surgical for $725 million aims to enhance its MedSurg portfolio, with the deal expected to be accretive to adjusted EPS beginning in 2027.
Mizuho Upgrades Solventum (SOLV), Cites Optimistic Dental Outlook, Acera Acquisition
Mizuho upgraded Solventum (SOLV) from Neutral to Outperform, raising its price target to $100 due to an optimistic dental industry outlook and higher valuation estimates following the acquisition of Acera Surgical. Stifel also maintained a Buy rating, raising its price target to $105, citing a favorable outlook for large-cap MedTech in 2026. The Acera acquisition, specializing in regenerative wound care, is expected to enhance Solventum's MedSurg portfolio.
Mizuho Upgrades Solventum (SOLV), Cites Optimistic Dental Outlook, Acera Acquisition
Mizuho upgraded Solventum (SOLV) from Neutral to Outperform, raising its price target to $100 from $85, based on an optimistic dental industry outlook and the acquisition of Acera Surgical. Stifel also raised its price target for Solventum to $105, maintaining a Buy rating. The Acera acquisition, finalized for $725 million upfront, is expected to enhance Solventum's MedSurg portfolio, though it may be slightly dilutive to EPS in 2026 before becoming accretive in 2027.
Liquidity Mapping Around (SOLV) Price Events
This article provides an AI-driven analysis of Solventum Corporation (NASDAQ: SOLV) price events, identifying a neutral near-term sentiment with potential mid-term weakness. It details an exceptional risk-reward short setup and outlines three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis for support and resistance levels.
Solventum (NYSE:SOLV) Downgraded to "Hold" Rating by Wall Street Zen
Solventum (NYSE:SOLV) was downgraded to a "Hold" rating by Wall Street Zen. The company recently reported a quarterly EPS beat of $1.50 against estimates of $1.43 and announced a $1.0 billion share buyback program. Solventum currently has an average analyst rating of "Hold" with a consensus target price of $90.83.
A Legacy of Brighter Smiles: Celebrating 24 Years of the Give Kids A Smile Program
The American Dental Association Foundation's Give Kids A Smile (GKAS) program is celebrating its 24th year, having provided essential dental services to over 10.2 million underserved children since 2003. Kicking off nationally in February for National Children's Dental Health Month, the program aims to reach 325,000 children in 2026 through 1,200 events and 23,000 volunteers. Longtime sponsors Henry Schein and Colgate-Palmolive continue to provide crucial support through product donations and oral health education initiatives.
Align Technology (ALGN) Q4 EPS Beat Tests Bearish Earnings Narratives
Align Technology (ALGN) reported robust Q4 2025 results with US$1.0 billion in revenue and US$1.89 Basic EPS, prompting a re-evaluation of bearish narratives. While the company's TTM net profit margin is 10.2% and earnings are forecast to grow 15.7% annually, past five years saw a 21.6% decline, creating a mixed picture. Additionally, its 5% annual revenue growth lags the US market's 10.3% forecast, and its P/E ratio of 30.7x is slightly above peers, although a DCF fair value suggests potential undervaluation.
Sunrun stock jumps 12% as RUN touts record growth in “distributed power plant” programs
Sunrun (RUN) shares jumped 12% following an announcement of record growth in its "distributed power plant" programs, which saw customer participation surge over fivefold in 2025. The company's grid-services segment, where customers feed stored energy back to the grid, is seen as a key area for steady revenue in the residential solar market. Investors are now focused on Sunrun's upcoming earnings report on February 26 for further insights into cash flow and future guidance.
Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026
Solventum (NYSE: SOLV) announced it will release its fourth-quarter and full-year fiscal 2025 financial results on February 26, 2026, after market close. Following the release, the company will host a webcast to discuss the results and its fiscal year 2026 outlook. Details for the webcast and dial-in information have been provided for investors.
Solventum plans Feb. 26 webcast on 2025 results, 2026 outlook
Solventum (NYSE: SOLV) will report its fourth quarter and full fiscal year 2025 results on February 26, 2026, after the U.S. market closes. The company will host a webcast at 3:30 p.m. CST / 4:30 p.m. EST to discuss these results and provide an outlook for fiscal year 2026. This announcement sets expectations for investors, who may focus on acquisition integration, capital allocation, and the impact of 3M's S-3 resale registration.
Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026
Solventum (NYSE: SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, February 26, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast at 3:30 p.m. CST / 4:30 p.m. EST to discuss the results and fiscal year 2026 outlook. Details for accessing the webcast and dial-in information are provided, along with a statement about Solventum's mission in healthcare.
Here’s Why Diamond Hill Large Cap Fund Added Solventum (SOLV) to Its Portfolio
Diamond Hill Large Cap Fund recently added Solventum Corporation (NYSE: SOLV) to its portfolio, as detailed in its Q4 2025 investor letter. The fund believes Solventum, a healthcare company spun off from 3M in April 2024, will achieve improved growth and margins as a standalone entity, driven by a new management focus on revenue growth, optimized R&D, and an improved sales mix. Despite this addition, the fund maintains a cautious stance on AI-driven market enthusiasm, preferring fundamentally stable, cash-generative businesses.
Strs Ohio Decreases Stake in Solventum Corporation $SOLV
STRS Ohio significantly reduced its stake in Solventum Corporation by 86.5% during the third quarter, selling 22,525 shares and retaining 3,530 shares valued at $258,000. This move comes as Solventum reported strong third-quarter earnings, beating analyst estimates, and announced a new $1.0 billion share buyback program. Despite mixed analyst ratings, the company's financial performance signals a potentially undervalued stock, attracting both trimming and new investments from various institutional funds.
Independent Franchise Partners LLP Increases Stake in Solventum Corp
Independent Franchise Partners LLP acquired an additional 2,456,451 shares of Solventum Corp on December 31, 2025, increasing their total holdings to 15,355,691 shares. Despite Solventum Corp's recent stock decline and a GF Score of 27/100, this strategic move by Independent Franchise Partners, a London-based investment firm managing over $13.5 billion, indicates a strong conviction in the company's long-term potential within the medical devices and instruments industry. Other notable investors like HOTCHKIS & WILEY and Richard Pzena also hold significant stakes, highlighting the stock's appeal to value investors.
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results
Thermo Fisher Scientific (NYSE: TMO) announced strong financial results for Q4 and the full year 2025, with revenue growth of 7% and 4% respectively, and significant increases in both GAAP and adjusted EPS. The company highlighted successful capital deployment, including $13 billion in M&A, and strategic advancements in innovative products, commercial engines, and partnerships. CEO Marc N. Casper expressed confidence in the company's strong position for continued growth and value creation in 2026.
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results
Thermo Fisher Scientific (NYSE: TMO) reported strong financial results for the fourth quarter and full year 2025, with revenue growth of 7% and 4% respectively, and significant increases in diluted EPS. The company highlighted strategic advancements including new product launches, expansion of commercial partnerships, and successful capital deployment through M&A and shareholder returns. Thermo Fisher enters 2026 with a strong strategic position, aiming to deliver on its objectives and continue creating value.
SLV ETF Stock Analysis as Silver Price Jumps and Outflows Rise: Buy or Sell?
The iShares Silver ETF (SLV) recently hit an all-time high, with silver prices surging due to geopolitical tensions and the rising odds of a US government shutdown. Despite this rally, the article suggests a potential near-term bearish breakdown for SLV, citing a shooting star candlestick pattern, extreme RSI and PPO levels, and substantial outflows from smart money investors. Investors are advised to watch the $90 support level as a possible pullback looms.
Rep. J. French Hill Sells Kyndryl Holdings, Inc. (NYSE:KD) Shares
Representative J. French Hill sold a stake in Kyndryl Holdings, Inc. worth between $1,001 and $15,000 on December 31st from his HILL 1998 TRUST. Concurrently, he divested larger amounts from Pfizer, SFL, and Solventum. Kyndryl recently traded near $24.48, and analysts currently rate the stock as a "Moderate Buy" with a consensus price target of $38.
Why (SOLV) Price Action Is Critical for Tactical Trading
This article provides an in-depth tactical analysis of Solventum Corporation (NASDAQ: SOLV), highlighting weak near and mid-term sentiment but a neutral long-term outlook. It details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis, support, and resistance levels essential for tactical trading decisions.
Is Slowing Revenue And Expected Sales Decline Altering The Investment Case For ICU Medical (ICUI)?
ICU Medical (ICUI) is facing an investment reassessment due to its slow revenue growth over the past two years (2.1%) and an expected sales decline of 7.7% in the next year. This challenging demand outlook raises questions about the company's valuation, which some analysts believe is already at a premium to its fair price-to-sales multiple, despite trading below some intrinsic value estimates. The company's investment narrative now heavily relies on operational improvements, cost discipline, and integration execution to offset the weakening sales trajectory.
How Investors Are Reacting To Align Technology (ALGN) Margin Roadmap and New 0x3 Treatment Suite
Align Technology (ALGN) has outlined a strategy to expand its operating margin by at least 100 basis points in 2026, driven by past restructuring, technological innovation, and the launch of its new 0x3 product suite, which includes a three-year treatment product without built-in refinements. This initiative aims to address cost-conscious doctors and Dental Support Organizations, though the stock still faces risks like premium valuation and modest revenue growth. Investors are evaluating how this plan will impact Align's investment narrative, with varying fair value estimates among analysts.
This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Several top Wall Street analysts have upgraded their ratings for five different companies, including a bullish turn for Cisco Systems. Keybanc upgraded Solventum, Wolfe Research upgraded National Storage Affiliates Trust, Rothschild & Co upgraded Meta Platforms, Evercore ISI Group upgraded Cisco Systems, and Keefe, Bruyette & Woods upgraded Stewart Information Services Corp, with several target price increases. These upgrades indicate a positive outlook from these financial experts for the respective stocks.
What Analysts Are Saying About Solventum Stock
Six analysts have evaluated Solventum (NYSE: SOLV) over the past three months, resulting in an average price target of $96.50, a 12.21% increase from the previous average. Several analysts have raised their ratings and price targets, indicating a positive sentiment towards the company. Solventum, spun out from 3M in early 2024, shows strong financial metrics including a high net margin, ROE, and ROA, alongside a prudent debt management strategy.
Rep. J. French Hill Sells Off Shares of SFL Corporation Ltd. (NYSE:SFL)
Representative J. French Hill recently sold shares of SFL Corporation Ltd. (NYSE:SFL) from his "HILL 2012 TRUST" account, with the transaction valued between $15,001 and $50,000. This sale was part of several recent trades by Hill, including larger sales in Pfizer. SFL stock saw a slight dip and has a consensus "Hold" rating from analysts despite beating quarterly EPS estimates.
Freight Technologies launches premium AI logistics platform Zayren Pro
Freight Technologies Inc. (Nasdaq:FRGT) has launched Zayren Pro, an advanced AI-driven logistics platform building on its existing Zayren system. This premium service offers unlimited AI agent usage, a carrier self-onboarding portal, and procurement tools, focusing on the U.S.-Mexico cross-border shipping corridor. Zayren Pro aims to convert rate predictions into carrier bookings and will contribute to the company's subscription-based SaaS revenue.
What You Need To Know Ahead of Solventum Earnings Release
Solventum Corporation (SOLV), a healthcare company spun off from 3M, is set to announce its fiscal fourth-quarter earnings for 2025. Analysts anticipate a profit of $1.50 per share, up 6.4% year-over-year, and the company has consistently beaten consensus estimates in the past four quarters. Despite lagging behind broader market indices in stock performance, analysts maintain a "Moderate Buy" rating with a potential upside of 13.5%.
What You Need To Know Ahead of Solventum Earnings Release
Solventum Corporation (SOLV) is set to announce its fiscal fourth-quarter 2025 earnings, with analysts projecting a 6.4% increase in diluted EPS to $1.50. The company, a 3M healthcare spin-off, has a strong track record of beating consensus estimates in previous quarters and recently raised its full-year 2025 EPS guidance. Despite lagging benchmark indices in stock performance over the past year, analysts maintain a "Moderate Buy" rating for SOLV, anticipating a 13.5% upside from current levels.
Solventum (NYSE:SOLV) Upgraded at Mizuho
Mizuho has upgraded Solventum (NYSE:SOLV) from a "hold" to a "strong-buy" rating. Despite this, the consensus rating for the stock remains an average "Hold" with a price target of $90.27. The company recently surpassed earnings expectations, issued a share repurchase program, and saw increased institutional investment, indicating growing confidence in its performance.
Sodium Lauroyl Sarcosinate Market In-depth Insights, Business
Coherent Market Insights has published a new report on the Sodium Lauroyl Sarcosinate market, forecasting its trends, share, size, growth, opportunities, and forecast from 2026-2033. The report analyzes key market dynamics, including growth drivers, challenges, and competitive landscapes, and provides insights into market segmentation by application and region. It aims to assist businesses in making informed strategic decisions and identifying future profitability.
Anchor Capital Advisors LLC Sells 13,376 Shares of Solventum Corporation $SOLV
Anchor Capital Advisors LLC decreased its holdings in Solventum Corporation by 2.2%, selling 13,376 shares and retaining 597,911 shares valued at $43.65 million. This follows Solventum's announcement of a $1.0 billion stock repurchase program and stronger-than-expected quarterly earnings, with $1.50 EPS against a $1.43 consensus and $2.10B revenue. The company also provided FY2025 EPS guidance of $5.98-$6.08, while analysts project $6.58 EPS.
3M Is Constrained by Sluggish End-Markets, but Product Innovations Could Help Reignite Growth
3M is facing challenges due to sluggish end-markets, which are impacting its revenue growth. Despite concerns about ongoing PFAS-related liabilities, the company's settlements and the Solventum spinoff are seen as substantially reducing risks. Product innovations are highlighted as a potential avenue to reignite growth for the industrial stalwart, with an outsider CEO sought to address stagnation.
Q3 Rundown: Zimmer Biomet (NYSE:ZBH) Vs Other Surgical Equipment & Consumables - Diversified Stocks
This article provides a Q3 rundown of Zimmer Biomet (NYSE:ZBH) and other diversified surgical equipment and consumables stocks. It highlights Zimmer Biomet's mixed quarter with in-line revenue but weaknesses compared to peers, while STERIS (NYSE:STE) showed the strongest performance, and Solventum (NYSE:SOLV) had the slowest revenue growth but a significant stock price increase. The piece also discusses industry trends, including an aging population and increasing integration of AI and robotics, alongside challenges like regulatory compliance and pricing pressures.
The Great Industrial Turnaround: A Deep Dive into the New 3M (MMM) in 2026
3M (MMM) has undergone a significant transformation in the last two years, marked by the spin-off of Solventum and settlements of major legal liabilities. Under new CEO Bill Brown, the company has streamlined its focus on Safety & Industrial, Transportation & Electronics, and Consumer segments, leading to a 33% stock surge in 2025. While challenges like remaining litigation and cyclical exposure persist, opportunities for growth and multiple expansion are present, culminating in tomorrow's Q4 2025 earnings report as a critical test for sustained turnaround momentum.
Analysts Offer Insights on Healthcare Companies: GeneDx Holdings (WGS), Masimo (MASI) and REPRO-MED Systems (KRMD)
This article highlights bullish analyst sentiments for three healthcare companies: GeneDx Holdings (WGS), Masimo (MASI), and REPRO-MED Systems (KRMD). Analysts from Canaccord Genuity and Piper Sandler maintained Buy ratings for these companies, citing significant upside potential based on their average price targets. The reports detail specific analyst ratings, price targets, and average returns, underscoring optimism in the Healthcare sector.
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX)
Analysts have provided new ratings for Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) in the Healthcare sector. Bank of America Securities maintained a Hold rating on Solventum with an $85.00 price target, while JonesTrading reiterated a Buy rating on Praxis Precision Medicines with a $441.00 price target, indicating significant upside potential.
Assessing Align Technology (ALGN) Valuation After Recent Share Price Rebound And Modest Discount Signals
Align Technology (ALGN) has seen a recent share price rebound of 31.5% over the past three months, despite a 23.5% loss over the last year. The stock is currently trading at US$171.49, which analysts suggest is a modest 27.6% discount to its intrinsic value of around US$180.47, indicating it may be undervalued. However, its P/E ratio of 32.5x is higher than the industry average, suggesting the market is already paying a premium.
Understanding Momentum Shifts in (SOLV)
This article analyzes potential momentum shifts in Solventum Corporation (SOLV), highlighting weak near-term sentiment but an exceptional risk-reward setup targeting an 8.5% gain. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and offers multi-timeframe signal analysis for near, mid, and long-term perspectives.
Forward Industries (NASDAQ: FWDI) Provides Solana Treasury Update, Operational Highlights
Forward Industries (NASDAQ: FWDI) has provided an update on its Solana-focused treasury strategy, reporting over 133,450 SOL in staking rewards since September 2025. The company holds more than 6.98 million SOL in liquid treasury assets, nearly all staked, generating a 6.73% gross annual yield. FWDI also announced its SEC-registered shares are now live on the Solana blockchain and is testing a PropAMM with support from Galaxy Digital and Jump Crypto.
Why ICU Medical, Inc. (NASDAQ:ICUI) Could Be Worth Watching
ICU Medical, Inc. (NASDAQ:ICUI) has seen a significant share price rise of 36% recently but is still considered undervalued according to Simply Wall St's analysis, trading at US$155 against an intrinsic value of $257.03. While its top-line growth is expected to be a modest 8.5% in the coming years, the current undervaluation might present a buying opportunity for investors. However, potential investors are advised to consider other factors like capital structure, management's track record, and existing risks before making an investment decision.
Nordea Investment Management AB Has $54.88 Million Position in Solventum Corporation $SOLV
Nordea Investment Management AB increased its stake in Solventum Corporation by 3.5% in Q3 2025, bringing its total holdings to 758,847 shares valued at $54.88 million. This comes as Solventum's Board approved a $1.0 billion share repurchase program, suggesting management views the stock as potentially undervalued. Analysts hold a mixed view on SOLV, with a consensus "Hold" rating and an average target price of $88.64, although some recent upgrades have pushed targets higher.
Surgical Equipment & Consumables - Diversified Stocks Q3 Earnings: STERIS (NYSE:STE) Best of the Bunch
The article reviews Q3 earnings for diversified surgical equipment and consumables stocks. STERIS (NYSE:STE) emerged as the top performer, exceeding analyst expectations with strong revenue growth. Other companies like Solventum (NYSE:SOLV), BD (NYSE:BDX), Zimmer Biomet (NYSE:ZBH), and CONMED (NYSE:CNMD) also reported their results, with varied performances against expectations.
Should You Continue to Hold Thermo Fisher Stock in Your Portfolio Now?
Thermo Fisher Scientific (TMO) is positioned for growth through strategic acquisitions and a strong pipeline of innovative product launches, despite concerns about its solvency and exposure to foreign currency risks. The company has outperformed its industry in stock performance and boasts a solid earnings surprise history. Analysts recommend a "Hold" for TMO, while also highlighting other strong buy-rated stocks in the medical sector.
Solventum (SOLV): The 3M Spin-Off That Found Its Rhythm – A 2026 Deep-Dive Analysis
Solventum (SOLV) has successfully transformed since its 2024 spin-off from 3M, establishing itself as a focused medtech leader. The company aggressive debt reduction, divestitures, and strong performance in wound care and health informatics have significantly boosted its stock price, which is now near an all-time high. Solventum's strategic management and innovative product development position it as a compelling investment in 2026, despite continuing challenges related to rebranding and regulatory changes.
3 Reasons SOLV is Risky and 1 Stock to Buy Instead
This article analyzes Solventum (SOLV), highlighting three reasons why it might be a risky investment: slow organic growth, negative revenue projections from Wall Street analysts, and a dropping free cash flow margin. The author suggests cheering for Solventum from the sidelines and instead recommends exploring semiconductor stocks or other high-quality growth stocks that StockStory has identified with strong historical returns.
